Reasons to Retain Cooper Companies Stock in Your Portfolio for Now

• Premium lens products (MyDay multifocal, Energys, and toric lenses) grew over 15%, with operational restructuring delivering 20% increase in adjusted EPS and AI-driven automation improving margins
• Fiscal 2026 consensus estimates project 5.3% revenue growth to $4.31 billion and 12.4% EPS improvement to $4.63, with long-term earnings growth expected at 8.3% over five years
• Japan market weakness and competitive pressure on legacy hydrogel lenses offset gains, while CooperSurgical's fertility business faces uncertainty from China weakness and Middle East geopolitical tensions

Cooper Companies Stock Analysis Summary

Company Overview

The Cooper Companies (COO), a global specialty medical device company with a $13.36 billion market cap, has underperformed the broader market, declining 6% year-to-date versus the S&P 500's 10.3% gain and trailing its industry's 2% decline.

Key Performance Metrics

• Bottom line growth: Projected 8.3% improvement over five years
• Earnings consistency: Beat estimates in four consecutive quarters with 5.80% average surprise
• Q1 FY2026: Adjusted EPS increased 20% sequentially
• FY2026 outlook: Revenue consensus of $4.31 billion (5.3% growth); adjusted EPS of $4.63 (12.4% increase)
• Recent estimate revision: Fiscal 2026 EPS estimate rose 2 cents in past 60 days

Growth Drivers

CooperVision continues strong momentum with its 18th consecutive year of market share gains. Premium products (MyDay multifocal, Energys, toric lenses) grew over 15%, while myopia-management product MiSight shows encouraging adoption in Europe and Japan. Operational restructuring delivered substantial margin expansion through cost reductions and AI-driven automation.

The company enters H2 FY2026 with a robust product launch pipeline, including expanded MyDay and MiSight offerings and new branded/private-label contracts expected to contribute from Q3 onward.

Key Challenges

Japan remains problematic, with Asia-Pacific revenues declining due to competitive pressure on legacy hydrogel lenses. CooperSurgical's fertility business faces ongoing weakness in China, Middle East geopolitical uncertainty, and soft equipment installations. Rising competition across product categories, particularly in Asia-Pacific pricing and myopia-control alternatives, poses margin risks.

Investment Stance

Zacks Rank: Hold. While long-term opportunities remain strong, near-term execution challenges and regional headwinds warrant cautious positioning.